AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.37 |
Market Cap | 4.16M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -27.4 |
PE Ratio (ttm) | -0.01 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.38 |
Volume | 172,196 |
Avg. Volume (20D) | 3,691,852 |
Open | 0.37 |
Previous Close | 0.39 |
Day's Range | 0.36 - 0.38 |
52-Week Range | 0.31 - 4.00 |
Beta | undefined |
About CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...
Analyst Forecast
According to 1 analyst ratings, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 2872.97% from the latest price.
Next Earnings Release
Analysts project revenue of $10.00K, reflecting a -67.74% YoY shrinking and earnings per share of -0.29, making a -95.35% decrease YoY.